Nanotransfer
Nanotransfer is a science-driven nanobiotech company dedicated to reimagining gene therapy by developing a library of non-viral, safe, efficient, and cost-effective delivery systems based on metal oxide nanoparticles. Their mission is to unlock the full potential of gene therapies, making them accessible and impactful for patients worldwide. The company focuses on creating ready-to-use, target-specific, and re-treatable delivery vehicles capable of carrying various nucleic acids and editing tools like CRISPR, with applications in in-vitro, ex-vivo, and in-vivo gene therapies.
Industries
Nr. of Employees
small (1-50)
Nanotransfer
Sunnyvale, California, United States, North America
Products
Non-viral metal-oxide nanoparticle delivery platform
A library of metal-oxide-based nanoparticle vehicles formulated for delivery of various nucleic acids and gene-editing tools across in vitro, ex vivo and in vivo applications.
Non-viral metal-oxide nanoparticle delivery platform
A library of metal-oxide-based nanoparticle vehicles formulated for delivery of various nucleic acids and gene-editing tools across in vitro, ex vivo and in vivo applications.
Services
Vehicle selection consulting
Technical support to choose an appropriate nanoparticle vehicle based on payload size and target cell or tissue.
Gene-vehicle integration service
Operational workflow service for integrating genetic cargo with nanoparticle vehicles via a straightforward mixing/integration step to produce a ready-to-use preparation.
Targeted delivery development
Development projects to tune nanoparticle properties for tissue- or cell-specific targeting of genetic payloads.
Ex vivo therapy collaboration and development
Collaborative programs to advance ex vivo gene therapy approaches, with an expressed focus on primary genetic immunodeficiencies.
Vehicle selection consulting
Technical support to choose an appropriate nanoparticle vehicle based on payload size and target cell or tissue.
Gene-vehicle integration service
Operational workflow service for integrating genetic cargo with nanoparticle vehicles via a straightforward mixing/integration step to produce a ready-to-use preparation.
Targeted delivery development
Development projects to tune nanoparticle properties for tissue- or cell-specific targeting of genetic payloads.
Ex vivo therapy collaboration and development
Collaborative programs to advance ex vivo gene therapy approaches, with an expressed focus on primary genetic immunodeficiencies.
Expertise Areas
- Non-viral gene delivery
- Metal-oxide nanoparticle engineering
- Tissue-targeted delivery
- CRISPR and gene-editing delivery
Key Technologies
- Metal-oxide nanoparticles
- Non-viral nucleic acid delivery
- CRISPR/Cas delivery
- Nanoparticle surface engineering